Comparison · NCT03241030-a55b93d4
Experimental Group vs Placebo Group: Number of Participants That Require Intravenous Fluid Administration
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Experimental Group vs Placebo Group: Number of Participants That Require Intravenous Fluid Administration. Trial comparisons, record NCT03241030-a55b93d4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03241030-a55b93d4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.102 | 0.0444 | 0.218 | wilson | |
| Risk in group 2 | 0.0196 | 0.00347 | 0.103 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0824 | -0.019 | 0.199 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 5.2 | 0.63 | 43 | log | |
| Odds ratio, group 1 over group 2 | 5.68 | 0.639 | 50.5 | log | |
| Number needed to treat, for one more participant with the outcome on Experimental Group than on Placebo Group | 12.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Experimental Group | Subjects will receive sucralfate~Sucralfate: Will receive 20mg/kg/dose up to 1 gram.~Acetaminophen: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.~Ibuprofen: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo. | 5 | 49 | OG000 |
| Group 2 | Placebo Group | Subjects will receive a placebo~Placebo: Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.~Acetaminophen: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.~Ibuprofen: All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo. | 1 | 51 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants That Require Intravenous Fluid Administration
- Description
- To explore the difference in the rates of intravenous fluid (IVF) administration in children treated with sucralfate versus placebo.
- Time frame
- 6 hours from the time of enrollment
- Population
Source ClinicalTrials.gov
Trial
- Title
- Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial
- NCT number
- NCT03241030
- Phases
- PHASE2
- Conditions
- Herpangina, Gingivostomatitis, Hand, Foot and Mouth Disease
- Interventions
- Sucralfate, Placebo, Acetaminophen, Ibuprofen
- Lead sponsor
- University of Texas at Austin
- Results first posted
- 2021-10-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03241030?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03241030-a55b93d4